The cardiac endocrine aldosterone system

Current Opinion in Endocrinology and Diabetes

Volumn 6, Issue 3, 1999, Pages 204-209

  Silvestre, Jean Sébastien ^a   Robert, Valérie ^a   Delcayre, Claude ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE RECEPTOR; ANGIOTENSIN; MINERALOCORTICOID;

ADRENAL GLAND; ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; ENDOCRINE SYSTEM; EPITHELIUM; HEART; HEART MUSCLE FIBROSIS; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; ION TRANSPORT; NONHUMAN; PARACRINE SIGNALING; RAT;

EID: 0033059903     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199906000-00006     Document Type: Article

References (46)

1. + ATPase.
2. Agarwal MK, Philippe M: Physical characterization of corticosteroid binders in adult rat heart. J Mol Cell Cardiol 1979, 11:115-126.
3. Lombès M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP: Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992, 71:503-510.
4. Lombès M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP: Prerequiste for cardiac aldosterone action. Mineralocorticoid receptor and 11b-hydroxysteroid dehydrogenase in the human heart. Circulation 1995, 92:175-182.
5. Funder JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242:583-585.
6. Slight SH, Ganjam VK, Gomez-Sanchez CE, Zhou MY, Weber KT: High affinity NAD+-dependent 11β-hydroxysteroid dehydrogenase in the human heart. J Mol Cell Cardiol 1996, 28:781-787.
7. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC: Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997, 95:1471-1478. This article shows that aldosterone excess is associated with both increased left ventricular wall thickness and mass and decreased early diastolic left ventricular filling indexes of the human heart.
8. Swedberg K, Eneroth P, Kjekshus J, Wilhelmesen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS trial study group. Circulation 1990, 82:1730-1736.
9. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al.: Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998, 273:4883-4891. These authors demonstrate the existence of a functional steroidogenic system in cardiac tissue.
10. Pearce P, Funder JW: High affinity aldosterone binding sites (type I receptors in rat heart). Clin Exp Pharmacol Physiol 1987, 14:859-866.
11. Zennaro MC, Le Menuet D, Viengchareun S, Walker F, Ricquier D, Lombes M: Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J Clin Invest 1998, 101:1254-1260. This article analyzes the regulatory mechanisms controlling tissue-specific expression of MR and shows that transgenic mice expressing the SV40 large T antigen under the control of the P1 promoters of the hMR gene died of malignant liposarcomas originating in brown adipose tissue.
12. Lombès M, Kenouch S, Souque A, Farman N, Rafestin-Oblin ME: The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11b-hydroxysteroid dehydrogenase. Endocrinology 1994, 135:834-840.
13. Walker BR, Yau JL, Brett LP, Seckl JR, Monder C, Williams BC, Edwards CRW: 11β-hydroxysteroid dehydrogenase in vascular smooth muscle and heart: Implications for cardiovascular responses to glucocorticoids. Endocrinology 1991, 129:3305-3310.
14. Fejes-Toth G, Pearce D, Naray-Fejes-Toth A: Subcellular localization of mineralocorticoid receptors in living cells: Effects of receptor agonists and antagonists. Proc Natl Acad Sci U S A 1998, 95:2973-2978. This article addresses the subcellular localization of MR and shows that the hormone-activated MR complexes cluster in the cell nucleus only with transcriptionally active mineralocorticoids.
15. Lim-Tio SS, Fuller PJ: Intracellular signaling pathways confer specificity of transactivation by mineralocorticoid and glucocorticoid receptors. Endocrinology 1998, 139:1653-1661. This article identifies several signal transduction pathways that differentially activate either MR or GR, conferring MR- and GR-specific regulation.
16. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M: Estrogen receptor associated proteins: Possible mediators of hormone-induced transcription. Science 1994, 264:1455-1458.
17. Kurukowa R, Soderstrom M, Horlein A, Halachmi S, Brown M, Rosenfeld MG, Glass CK: Polarity-specific activities of retinoic acid receptors determined by a nuclear co-repressor. Nature 1995, 377:451-454.
18. Verrey F, Kraehenbuhl JP, Rossier BC: Aldosterone induces a rapid increase in the rate of Na,K-ATPase gene transcription in cultured kidney cells. Mol Endocrinol 1989, 3:1369-1376.
19. Ikeda U, Hyman R, Smith TW, Medford RM: Aldosterone-mediated regulation of Na,K-ATPase gene expression in adult and neonatal rat cardiocytes. J Biol Chem 1991, 266:12058-12066.
20. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, et al.: Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995, 26:971-978.
21. + ATPase.
22. Korichneva I, Puceat M, Millanvoye-Van Brussel E, Geraud G, Vassort G. Aldosterone modulates both the Na/H antiport and Cl/HCO3 exchanger in cultured neonatal rat cardiac cells. J Mol Cell Cardiol 1995, 27:2521-2528.
23. Sato A, Funder JW: High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 1996, 137:4145-4153.
24. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990, 67:1355-1364.
25. Funder JW: Aldosterone, salt and cardiac fibrosis. Clin Exp Hypertens 1997, 19:885-899.
26. Brilla C, Matsubara LS, Weber KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25:563-575.
27. Robert V, Nguyen VT, Cheav SL, Mouas C, Swynghedauw B, Delcayre C: Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994, 24:30-36.
28. Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994, 93:2578-2583.
29. Robert V, Besse S, Sabri A, Silvestre JS, Assayag P, Nguyen VT, et al.: Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest 1997, 76:729-738.
30. Robert V, Heymes C, Silvestre JS, Swynghedauw B, Delcayre C: Angiotensin AT1 receptor subtype is a cardiac target of aldosterone. Role in aldosterone-salt induced fibrosis. Hypertension 1999, 33:in press.
31. Hou J, Kato H, Cohen RA, Chobanian AV, Brecher P: Angiotensin II-induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase. J Clin Invest 1995, 96:2469-2477.
32. Karam H, Heudes D, Hess P, Gonzales MF, Loffler BM, Clozel M, Clozel JP: Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats. Cardiovasc Res 1996, 31:287-295.
33. Fareh J, Touyz RM, Schiffrin EL, Thibault G: Cardiac type-1 angiotensin II receptor status in deoxycorticosterone acetate-salt hypertension in rats. Hypertension 1997, 30:1253-1259.
34. Ramires FJA, Sun Y, Weber KT: Myocardial fibrosis associated with aldosterone or angiotensin II administration: Attenuation by calcium channel blockade. J Mol Cell Cardiol 1998, 30:475-483.
35. Wehling M, Neylon CB, Fullerton MJ, Bobik A, Funder JW: Nongenomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells. Circ Res 1995, 76:973-979.
36. Sato A, Liu JP, Funder JW: Aldosterone rapidely represses protein kinase C activity in neonatal rat cardiomyocytes in vitro. Endocrinology 1997, 138:3410-3416. This article discusses the nongenomic effect of aldosterone in neonatal rat cardiomyocytes.
37. Wehling M, Spes CH, Win N, Janson CP, Schmidt BM, Theisen K, Christ M: Rapid cardiovascular action of aldosterone in man. J Clin Endocr Metab 1998, 83:3517-3522. This article was the first demonstration of rapid nongenomic effects of aldosterone on human cardiovascular functions.
38. +, and cAMP-signaling pathways use the same SF-1 and CRE-like cia-elements to regulate human CYP11B2 gene expression.
39. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF, Gomez. Sanchez EP: Aldosterone biosynthesis in the ral brain. Endocrinology 1997, 138:3369-3373. This article demonstrates the existence of the enzymatic machinery involved in adrenal corlicosteroid synthesis and aldosterone production in the rat brain.
40. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H: Vascular aldosterone. Biosynthesis and a link to angiotensin II induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994, 269:24316-24320.
41. Knox JR, Lockett MF: Similarity between a substance produced by the heart in vitro and the 18-monoacetyl derivative of D-aldosterone. J Endocrinol 1969, 43:315-316.
42. Zhao HF, Labrie C, Simard J, De Launoit Y, Trudel C, Martel C, et al.: Characterisation of rat 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase cDNAs and differential tissue-specific expression of the corresponding mRNAs in steroidogenic and peripheral tissues. J Biol Chem 1991, 266:583-593.
43. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, et al.: Production of aldosterone in isolated rat blood vessels. Hypertension 1995, 25:170-173.
44. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Inaba S, et al.: Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996, 81:2797-2800.
45. Ullian ME, Schelling JR, Linas SL: Aldo enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992, 20:67-73.
46. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995, 76:1259-1265